{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:03:41Z","timestamp":1769605421694,"version":"3.49.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.semradonc.2012.03.010","type":"journal-article","created":{"date-parts":[[2012,6,9]],"date-time":"2012-06-09T03:45:30Z","timestamp":1339213530000},"page":"254-262","source":"Crossref","is-referenced-by-count":35,"title":["The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"James","family":"Brierley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semradonc.2012.03.010_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<493::AID-CNCR17>3.0.CO;2-U","article-title":"Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy","volume":"78","author":"Vassilopoulou-Sellin","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0002-9610(99)80332-8","article-title":"Age correlates with increased frequency of high risk factors in elderly patients with thyroid cancer","volume":"170","author":"Coburn","year":"1995","journal-title":"Am J Surg"},{"key":"10.1016\/j.semradonc.2012.03.010_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2214\/ajr.97.4.923","article-title":"Radiation therapy in the control of persistent thyroid cancer","volume":"97","author":"Sheline","year":"1966","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"10.1016\/j.semradonc.2012.03.010_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0360-3016(01)02686-4","article-title":"Papillary thyroid carcinoma: Prognostic factors and the role of radioiodine and external radiotherapy","volume":"52","author":"Chow","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl9","key":"10.1016\/j.semradonc.2012.03.010_bib5","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19850501)55:9+<2062::AID-CNCR2820551406>3.0.CO;2-O","article-title":"External radiotherapy in thyroid cancers","volume":"55","author":"Tubiana","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0030-6665(20)31272-X","article-title":"Radioiodine and radiotherapy in the management of thyroid cancers","volume":"23","author":"Simpson","year":"1990","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.semradonc.2012.03.010_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0959-8049(94)90284-4","article-title":"Results of external beam radiotherapy in differentiated thyroid carcinoma: A retrospective study from the Royal Marsden Hospital","volume":"30A","author":"O'Connell","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib8","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/183461","article-title":"Differentiated thyroid cancer with extrathyroidal extension: Prognosis and the role of external beam radiotherapy","author":"Sia","year":"2010","journal-title":"J Thyroid Res"},{"key":"10.1016\/j.semradonc.2012.03.010_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/thy.1996.6.305","article-title":"Medullary thyroid cancer\u2014Analyses of survival and prognostic factors and the role of radiation therapy in local control","volume":"6","author":"Brierley","year":"1996","journal-title":"Thyroid"},{"key":"10.1016\/j.semradonc.2012.03.010_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0360-3016(88)90381-1","article-title":"Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients","volume":"14","author":"Simpson","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib11","first-page":"399","article-title":"Postoperative irradiation for thyroid cancer","volume":"19","author":"Phlips","year":"1993","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<172::AID-CNCR28>3.0.CO;2-1","article-title":"Differentiated thyroid cancer","volume":"77","author":"Farahati","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<389::AID-CNCR19>3.0.CO;2-V","article-title":"The effects of surgery, radioiodine and external radiation therapy on the clinical outcome of patients with differentiated thyroid cancer","volume":"82","author":"Tsang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0936-6555(03)00162-6","article-title":"External beam radiotherapy in the management of differentiated thyroid cancer","volume":"15","author":"Ford","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.semradonc.2012.03.010_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0360-3016(02)04203-7","article-title":"Value of external irradiation for locally advanced papillary thyroid cancer","volume":"55","author":"Kim","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2265.2005.02358.x","article-title":"Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years","volume":"63","author":"Brierley","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.semradonc.2012.03.010_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijrobp.2005.12.010","article-title":"The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea","volume":"65","author":"Keum","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.amjoto.2005.05.017","article-title":"External beam radiotherapy for differentiated thyroid cancer","volume":"27","author":"Meadows","year":"2006","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ijrobp.2008.05.012","article-title":"Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering cancer center experience","volume":"73","author":"Terezakis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2008.09.023","article-title":"Postoperative external beam radiotherapy for differentiated thyroid cancer: Outcomes and morbidity with conformal treatment","volume":"74","author":"Schwartz","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.semradonc.2012.03.010_bib22","series-title":"British Thyroid Association: Guidelines for the management of thyroid cancer in adults","year":"2006"},{"key":"10.1016\/j.semradonc.2012.03.010_bib23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3413\/nukmed-0221","article-title":"Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer\u2014Results after 874 patient-years of follow-up in the MSDS-trial","volume":"48","author":"Biermann","year":"2009","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.semradonc.2012.03.010_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.radonc.2008.05.023","article-title":"Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation","volume":"89","author":"Azrif","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1089\/10507250152741028","article-title":"Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine","volume":"11","author":"Wang","year":"2001","journal-title":"Thyroid"},{"key":"10.1016\/j.semradonc.2012.03.010_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","article-title":"Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning","volume":"91","author":"Robbins","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jso.21557","article-title":"Adjuvant external beam radiation for medullary thyroid carcinoma","volume":"102","author":"Martinez","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0748-7983(96)92294-5","article-title":"Medullary thyroid cancer: The role of radiotherapy in local control","volume":"22","author":"Fife","year":"1996","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib29","first-page":"30","article-title":"The value of postoperative radiotherapy for regional medullary carcinoma of the thyroid","author":"Mak","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hed.20791","article-title":"Postoperative radiotherapy for advanced medullary thyroid cancer\u2014Local disease control in the modern era","volume":"30","author":"Schwartz","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.semradonc.2012.03.010_bib31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American thyroid association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.semradonc.2012.03.010_bib32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clon.2004.07.013","article-title":"Anaplastic thyroid cancer in British Columbia 1985-1999: A population-based study","volume":"17","author":"Goutsouliak","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.semradonc.2012.03.010_bib33","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","article-title":"Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival","volume":"91","author":"Haigh","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib34","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/cncr.22203","article-title":"Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens","volume":"107","author":"Wang","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11864-000-0051-8","article-title":"Anaplastic thyroid carcinoma","volume":"1","author":"Haigh","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib36","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1002\/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO;2-1","article-title":"Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy","volume":"60","author":"Kim","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.semradonc.2012.03.010_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","article-title":"Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy","volume":"60","author":"De Crevoisier","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2012.03.010_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/EJE-06-0677","article-title":"Anaplastic thyroid carcinoma: Clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years","volume":"156","author":"Brignardello","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.radonc.2009.02.016","article-title":"Multimodality treatment for anaplastic thyroid carcinoma\u2014Treatment outcome in 75 patients","volume":"92","author":"Swaak-Kragten","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.radonc.2011.09.004","article-title":"Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review","volume":"101","author":"Sherman","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.radonc.2011.09.004","article-title":"Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review","volume":"101","author":"Sherman","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib42","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1210\/jc.2009-2827","article-title":"High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel","volume":"95","author":"Troch","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/thy.2000.10.587","article-title":"Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion","volume":"10","author":"Ain","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.semradonc.2012.03.010_bib44","first-page":"27","article-title":"Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid (ATC)","author":"Nagaiah","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.6057","article-title":"Phase II trial evaluating imatinib (I) in patients (pts) with anaplastic thyroid carcinoma (ATC)","author":"Ha","year":"2009","journal-title":"J Clin Oncol 27"},{"key":"10.1016\/j.semradonc.2012.03.010_bib46","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib47","first-page":"29","article-title":"A randomized phase II\/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial","author":"Sosa","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib48","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2008.02.001","article-title":"External beam radiation therapy for thyroid cancer","volume":"37","author":"Brierley","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.semradonc.2012.03.010_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1748-717X-5-69","article-title":"The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer","volume":"5","author":"Kim","year":"2010","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib50","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-8140(01)00382-6","article-title":"Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland","volume":"60","author":"Nutting","year":"2001","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib51","author":"Brierley"},{"key":"10.1016\/j.semradonc.2012.03.010_bib52","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.17.3682","article-title":"Refractory thyroid cancer: A paradigm shift in treatment is not far off","volume":"26","author":"Pfister","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib53","first-page":"1454","article-title":"High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma","volume":"63","author":"Kimura","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2012.03.010_bib54","first-page":"259","article-title":"Genetics of papillary thyroid cancer initiation: Implications for therapy","volume":"116","author":"Fagin","year":"2005","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"10.1016\/j.semradonc.2012.03.010_bib55","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1210\/jc.2003-030838","article-title":"BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas","volume":"88","author":"Nikiforova","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib56","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2012.03.010_bib57","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1210\/jc.2007-1184","article-title":"Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase \u00bd inhibitor AZD6244","volume":"92","author":"Ball","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib58","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1210\/jc.2007-2825","article-title":"BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines","volume":"93","author":"Leboeuf","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib59","first-page":"28","article-title":"Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements","author":"Lucas","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib60","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.semradonc.2012.03.010_bib61","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","article-title":"An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten+\/\u2212 mice","volume":"98","author":"Podsypanina","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semradonc.2012.03.010_bib62","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semradonc.2012.03.010_bib63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.semradonc.2012.03.010_bib64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.clpt.6100317","article-title":"Rapamycin: Something old, something new, sometimes borrowed and now renewed","volume":"82","author":"Hartford","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semradonc.2012.03.010_bib65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0002-9610(98)00238-4","article-title":"Tumor vascularity predicts recurrence in differentiated thyroid carcinoma","volume":"176","author":"Dhar","year":"1998","journal-title":"Am J Surg"},{"key":"10.1016\/j.semradonc.2012.03.010_bib66","first-page":"1343","article-title":"Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma","volume":"5","author":"Ishiwata","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/j.semradonc.2012.03.010_bib67","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.82.11.3741","article-title":"Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid","volume":"82","author":"Soh","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib68","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/sj.onc.1201456","article-title":"Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1\/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization","volume":"15","author":"Viglietto","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.semradonc.2012.03.010_bib69","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1089\/105072502320908286","article-title":"Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice","volume":"12","author":"Bauer","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.semradonc.2012.03.010_bib70","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.surg.2008.07.027","article-title":"The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma","volume":"144","author":"Yu","year":"2008","journal-title":"Surgery"},{"key":"10.1016\/j.semradonc.2012.03.010_bib71","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0002-9440(10)65515-0","article-title":"Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features","volume":"155","author":"Bunone","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib72","first-page":"1569","article-title":"Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines","volume":"11","author":"Viglietto","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.semradonc.2012.03.010_bib73","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1210\/jc.86.2.656","article-title":"Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma","volume":"86","author":"Klein","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semradonc.2012.03.010_bib74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/msy.2001.112592","article-title":"Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer","volume":"129","author":"Lennard","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.semradonc.2012.03.010_bib75","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib76","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2008.18.2717","article-title":"Phase II trial of sorafenib in metastatic thyroid cancer","volume":"27","author":"Kloos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib77","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2012.03.010_bib78","first-page":"26","article-title":"Phase 2 study of sunitinib in refractory thyroid cancer","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib79","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2012.03.010_bib80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semradonc.2012.03.010_bib81","first-page":"29","article-title":"A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC)","author":"Sherman","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342961200029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105342961200029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T03:28:48Z","timestamp":1642390128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105342961200029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S105342961200029X"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2012.03.010","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}